DRG Market Assessment reports

First-line treatment for non-small-cell lung cancer (NSCLC) patients without driver mutations typically includes an immune checkpoint inhibitor, with or without platinum-based chemotherapy,…

Topical therapies are the backbone of psoriasis management; however, they are often inadequate for patients with moderate to severe disease, who typically require systemic treatment. While…

Standard treatments for eosinophilic esophagitis (EoE) typically include proton pump inhibitors (PPIs) and swallowed topical steroids. Although these therapies can alleviate EoE symptoms, their…

The severe to very severe chronic COPD market is crowded, with numerous LAMA, LABA/ICS, LABA/LAMA, and triple LABA/LAMA/ICS inhalers competing for use. Although dual and triple longacting…

Multiple system atrophy (MSA) is a rare, rapidly progressing neurodegenerative synucleinopathy that disrupts movement, balance, and autonomic function. Current management comprises only symptomatic…

The unresectable locally advanced or metastatic bladder cancer treatment landscape continues to evolve, driven by the integration of immunotherapy, targeted agents, and antibody–drug conjugates (…

Thyroid eye disease (TED) is a rare, vision-threatening autoimmune disorder that typically begins with an active inflammatory phase before progressing to a chronic stage. Amgen’s Tepezza is…

Cystic fibrosis (CF) is a genetic disease associated with more than 2,000 mutations identified in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. These mutations cause aberrant…

Myasthenia gravis (MG) is a rare autoimmune disorder in which antibodies impair acetylcholinemediated neuromuscular transmission, causing fluctuating muscle weakness. Generalized MG (gMG) often…

Over the past two decades, TNF-α inhibitors (AbbVie’s Humira, Amgen / Pfizer’s Enbrel, Johnson & Johnson Innovative Medicine’s Remicade and Simponi, and UCB’s Cimzia) have significantly…

Negative symptoms of schizophrenia—often occurring along with positive symptoms—include diminished emotional expression (affective flattening), reduced goal-directed behavior (avolition),…

The treatment landscape for paroxysmal nocturnal hemoglobinuria (PNH) has shifted dramatically in the past decade, moving beyond supportive care to transformative complement inhibition therapies…